Sonoma Pharmaceuticals, Inc. (SNOA)

Market Cap	7.18M +17.0%
Revenue (ttm)	17.72M +26.8%
Net Income	-3.37M
EPS	-2.04
Shares Out	6.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,812
Open	1.190
Previous Close	1.180
Day's Range	1.130 - 1.200
52-Week Range	0.850 - 6.920
Beta	1.28
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 16, 2026

About SNOA

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial c...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 25, 2007
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: SNOA
• Website: https://sonomapharma.com

Financial Performance

In fiscal year 2025, Sonoma Pharmaceuticals's revenue was $14.29 million, an increase of 12.19% compared to the previous year's $12.74 million. Losses were -$3.46 million, -28.50% less than in 2024.